This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.
At least 18 years old and has provided informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histologically or cytologically confirmed PDAC with metastatic disease.
Evidence of active disease progression during or following the most recent line of systemic therapy for PDAC, based on investigator assessment.
History of known central nervous system metastatic disease.
Concurrent systemic anticancer therapy.
Significant cardiovascular disease.
Major GI conditions that may affect the ability to take or absorb daraxonrasib (patients with prior Whipple procedure are eligible).
Revolution Medicines, Inc.
Lead sponsor